{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T17:55:06Z","timestamp":1757699706213,"version":"3.33.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[1986,12,1]],"date-time":"1986-12-01T00:00:00Z","timestamp":533779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[1986,12,1]],"date-time":"1986-12-01T00:00:00Z","timestamp":533779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[1986,12]]},"DOI":"10.1136\/ard.45.12.1012","type":"journal-article","created":{"date-parts":[[2008,7,28]],"date-time":"2008-07-28T23:49:46Z","timestamp":1217288986000},"page":"1012-1018","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Low dose intravenous 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD) for the treatment of Paget's disease of bone."],"prefix":"10.1016","volume":"45","author":[{"given":"J.A","family":"Cantrill","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.M","family":"Buckler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.C","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"278","DOI":"10.5694\/j.1326-5377.1981.tb128316.x","article-title":"Paget's disease of bone: experience","volume":"2","author":"S, Grunstein H.; P, Clifton; M, Bligh; S, Posen","year":"1981","unstructured":"Grunstein H S, Clifton P, Bligh M, Posen S. Paget's disease of bone: experience with 100 patients treated with salmon calcitonin. Med J Aust 1981; 2: 278-80.","journal-title":"Med J Aust"},{"key":"ref_2","first-page":"928","article-title":"Development and significance of antibodies to salmon calcitonin in patients with Paget's disease on long-term treatment","volume":"ii:","author":"Y, Woodhouse N.J.; M, Mohamedally S.; F, Saed-Nejad; J, Martin T.","year":"1977","unstructured":"Woodhouse N J Y, Mohamedally S M, Saed-Nejad F, Martin T J. Development and significance of antibodies to salmon calcitonin in patients with Paget's disease on long-term treatment. Br Med J 1977; ii: 928-9.","journal-title":"Br Med J"},{"key":"ref_3","first-page":"106","article-title":"Treatment of Paget's disease of bonc with mithramycin","volume":"127","author":"G, Ryan W.","year":"1977","unstructured":"Ryan W G. Treatment of Paget's disease of bonc with mithramycin. Clin Orthorp 1977; 127: 106-10.","journal-title":"Clin Orthorp"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0307-742X(21)00090-4","article-title":"Treatment of Paget's disease of bone","volume":"5","author":"G, Russell R.G.","year":"1979","unstructured":"Russell R G G. Treatment of Paget's disease of bone. Cliti Rheum Dis 1979; 5: 673-95.","journal-title":"Cliti Rheum Dis"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1210\/jcem-44-1-96","article-title":"Diphosphonate therapy of Paget's disease","volume":"44","author":"Canfield, R.; Rosner, W.; Skinner, J.","year":"1977","unstructured":"Canfield R, Rosner W, Skinner J, et al. Diphosphonate therapy of Paget's disease. J Clin Endocrinol Metab 1977; 44: 96-106.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref_6","first-page":"821","article-title":"Focal osteomalacia due to low dose diphosphonate therapy in Paget's disease","volume":"i:","author":"T, I.","year":"1984","unstructured":"I T. Focal osteomalacia due to low dose diphosphonate therapy in Paget's disease. Lancet 1984; i: 821-4.","journal-title":"Lancet"},{"key":"ref_7","first-page":"489","article-title":"Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone","volume":"ii:","author":"J, Meunier P.; C, Chapuy M.; C, Alexandre","year":"1979","unstructured":"Meunier P J, Chapuy M C, Alexandre C, et al. Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone. Lancet 1979; ii: 489-92.","journal-title":"Lancet"},{"key":"ref_8","first-page":"1474","article-title":"Intravenous clodronate in the treatment and retreatment of Paget's disease of the bone","volume":"i:","author":"P, Yates A.J.; C, Percival R.; S, Gray R.E.","year":"1985","unstructured":"Yates A J P, Percival R C, Gray R E S, et al. Intravenous clodronate in the treatment and retreatment of Paget's disease of the bone. Lancet 1985; i: 1474-7.","journal-title":"Lancet"},{"key":"ref_9","first-page":"799","article-title":"Treatment of Paget's disease with 3-amino-1-hydroxypropylidene-1,1bisphosphonate (APD)","volume":"i:","year":"1979","unstructured":"Frijlink W B, T'evelde J, Bijvoet 0 L M, Heynen G. Treatment of Paget's disease with 3-amino-1-hydroxypropylidene-1,1bisphosphonate (APD). Lancet 1979; i: 799-803.","journal-title":"Lancet"},{"key":"ref_10","first-page":"29","article-title":"Clinical and biological effects of low dose 3-amino-1-hydroxypropylidene-1,1-biphosphonate (APD) in Paget's disease of the bone","volume":"11","year":"1982","unstructured":"Heynen G, Delwaide P, Bijvoet 0 L M, Franchimont P. Clinical and biological effects of low dose 3-amino-1-hydroxypropylidene-1,1-biphosphonate (APD) in Paget's disease of the bone. Eur J Clin Invest 1982; 11: 29-35.","journal-title":"Eur J Clin Invest"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1259\/0007-1285-58-693-831","article-title":"Bijvoet 0 L M. Radiological demonstration of healing in Paget's disease of bone treated with APD","volume":"58","author":"R, Vellenga C.J.L.; D, Mudler J.","year":"1985","unstructured":"Vellenga C J L R, Mudler J D, Bijvoet 0 L M. Radiological demonstration of healing in Paget's disease of bone treated with APD. Br J Radiol 1985; 58: 831-7.","journal-title":"Br J Radiol"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/0041-008X(73)90219-6","article-title":"Intestinal absorption of disodium ethane-1-hydroxy-1,1-diphosphonate using a devolution technique","volume":"24","author":"R, Recker R.; D, Saville P.","year":"1973","unstructured":"Recker R R, Saville P D. Intestinal absorption of disodium ethane-1-hydroxy-1,1-diphosphonate using a devolution technique. Toxicol Appl Pharmacol 1973; 24: 580-9.","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1136\/bmj.288.6420.828-a","article-title":"Side effects of disodium aminohydroxypropylidene diphosphonate (APD) during treatment of bone disorders","volume":"288","author":"A, Mautalen C.; A, Casco C.; D, Gonzalez","year":"1984","unstructured":"Mautalen C A, Casco C A, Gonzalez D, et al. Side effects of disodium aminohydroxypropylidene diphosphonate (APD) during treatment of bone disorders. Br Med J 1984; 288: 828-9.","journal-title":"Br Med J"},{"key":"ref_14","first-page":"239","article-title":"Comparison of inravenous (3-amino-ihydroxypropylidene)-1,1-bisphosphonate and volume repletion in tumour induced hypercalcaemia","volume":"ii:","year":"1983","unstructured":"Sleeboom H P, Bijvoet 0 L M, van Oosterom A T, Gleed J H, O'Riordan J L H. Comparison of inravenous (3-amino-ihydroxypropylidene)-1,1-bisphosphonate and volume repletion in tumour induced hypercalcaemia. Lancet 1983; ii: 239-43.","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/ard.44.1.34","article-title":"Clinical experience with the use of two diphosphonates in the treatment of Paget's disease","volume":"44","author":"Dewis, P.; K, Prasad B.; C, Anderson D.; Willets, S.","year":"1985","unstructured":"Dewis P, Prasad B K, Anderson D C, Willets S. Clinical experience with the use of two diphosphonates in the treatment of Paget's disease. Ann Rheum Dis 1985; 44: 34-8.","journal-title":"Ann Rheum Dis"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/0041-008X(72)90007-5","article-title":"Metabolism of disodium ethane-1-hydroxy-1,1-diphosphonate (disodium etidronate) in the rat, rabbit, dog and monkey","volume":"21","author":"R, Michael W.; R, King W.; M, Wakim J.","year":"1972","unstructured":"Michael W R, King W R, Wakim J M. Metabolism of disodium ethane-1-hydroxy-1,1-diphosphonate (disodium etidronate) in the rat, rabbit, dog and monkey. Toxicol Appl Pharmacol 1972; 21: 503-15.","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref_17","first-page":"856","article-title":"Sodium etidronate in the treatment of Paget's disease of bone","volume":"87","author":"A, Khairi M.R.; D, Altman R.; P, De Rosa G.; J, Zimmerman; K, Shenk R.; C, Johnston C.","year":"1977","unstructured":"Khairi M R A, Altman R D, De Rosa G P, Zimmerman J, Shenk R K, Johnston C C. Sodium etidronate in the treatment of Paget's disease of bone. Ann Intern Med 1977; 87: 856-63.","journal-title":"Ann Intern Med"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1210\/jcem-42-3-459","article-title":"Paget's disease of bone: observations after cessation of long term synthetic calcitonin treatment","volume":"42","author":"Aramides, A.; Flores, A.; DeRose, J.; Wallach, S.","year":"1976","unstructured":"Aramides A, Flores A, DeRose J, Wallach S. Paget's disease of bone: observations after cessation of long term synthetic calcitonin treatment. J Clin Endocrinol Metab 1976; 42: 459-63.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1365-2265.1986.tb03254.x","article-title":"Absorption of oral diphosphonates in normal subjects","volume":"24","author":"Fogelman, I.; Smith, L.; Mazess, R.; A, Wilson M.; A, Bevan J.","year":"1986","unstructured":"Fogelman I, Smith L, Mazess R, Wilson M A, Bevan J A. Absorption of oral diphosphonates in normal subjects. Clin Endocrinol (Oxf) 1986; 24: 57-62.","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724126064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724126064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.45.12.1012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T05:59:53Z","timestamp":1737525593000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724126064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1986,12]]},"references-count":19,"journal-issue":{"issue":"12","published-print":{"date-parts":[[1986,12]]}},"alternative-id":["S0003496724126064"],"URL":"https:\/\/doi.org\/10.1136\/ard.45.12.1012","relation":{},"ISSN":["0003-4967"],"issn-type":[{"type":"print","value":"0003-4967"}],"subject":[],"published":{"date-parts":[[1986,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low dose intravenous 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD) for the treatment of Paget's disease of bone.","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.45.12.1012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 1986 \u00a9 THE AUTHORS. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology, EULAR. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}